Phase II Alliances Command the Most Interest
Biotechs have always relied on four sources of financing: venture capital, public equity, M&A, and alliances. But of these four financing "legs", only one remains strong: alliances. There's no question that average potential deal values-a combination of up-front fees and pre-commercialization money-are increasing nicely. But while the mean value of early-stage deals has remained steady, deal values for both Phase II and Phase III /NDA-stage compounds have continued to climb.
You may also be interested in...
At Windhover's March 2008 Pharmaceutical Strategic Outlook meeting one overriding theme was an alliance paradox: values continue to rise and deals provide an increasingly important source of funds for biotechs, yet public investors don't seem to like these deals. Plus: a discussion of big-pharma outlicensing and the importance of CFOs in pharma strategy.
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.